multidrugresistancemdr是指肿瘤细胞一旦对某种化疗药物产生耐.docVIP

急性髓细胞系白血病ERGIC－53基因与MDR1基因表达相关性研究 靳胜　张敏（北京世纪坛医院临检中心，北京，100038） [摘要]　目的: 探讨急性髓细胞系自血病(AMI )患者内质网高尔基体中间室标志物一53(ER—Golsiintermediate compartment一53，ERGIC一53)和多药耐药基因(mdr1)的相关关性表达及其与临床耐药和疗效的关系 方法: 用半定量逆转录聚合酶链反应(RT-PCR)检测HL60和HL60/ADR以及 KB和KBV200细胞系；同时检测34例AMI 患告16例非白血病患者和健康人的ERGIC－53基因和mdrl基因表达，分析ERGIC－53基因和mdrl基因表达的相关性及临床意义 结果：在KBV200细胞系中，ERGIC－53基因有较高表达；在AML患者中ERGIC－53基因和mdrl基因明显高于对照组，差异明显（P0.01）；在AML与对照组中，ERGIC－53基因和mdrl基因的表达有较好的相关性；ERGIC－53基因和mdrl基因的共表达与AML患者的临床分期以及治疗状况具有较高的相关性。结论：白血病患者的ERGIC－53基因和mdrl基因的共表达与患者的状态以及耐药密切相关，其可能参与恶性血液病的多药耐药过程，可以作为临床耐药诊断和判断预后的手段。 . 关键词：AML；肿瘤多药耐药；Mdr1；ERGIC－53 Expression and Correlation of ERGIC一53 gene and multidrug resistance gene in leukemia Jin sheng, zhangmin Center of clinical laboratory of Beijing Shijitan Hospital ，Beijing 100038，China； 【Abstract】 Objective: To study the relationship between sERGIC-53 gene and multidrug resistance gene(mdr1)，and their significance in clinical drug resistance andprognosis of acute myeloid leukemia(AMI )．Methods: Amplification of ERGIC-53 gene and mdrl gene in HL60/ADR, KBV200 cell line detected by semi?quantitative reverse transcription polymerase chain reaction(RT-PCR);at the same time monitored them in 34 AML patients and 16 normal controls; Results :The amplification of ERGIC-53 gene and mdrl gene in AML patients and KBV200 were significantly higher than that in the normal control(P0.01)，which were related to clinical drug resistan ce and prognosis．The amplification of ERGIC-53 gene was related to the amplification of mdrl gene in the two groups． Conclusion: The co-am plification of ERGIC-53 and mdrl gene Can be taken as a good indicator of clinical drug resistance and prognosis of AML ． 【Subject words】leukemia，acute myeloid cell； Multi—drug resistance；Mdr1；ERGIC-53 gene； 多药耐药(Multidrug resistance , MDR)是指肿瘤细胞一旦对某种化疗药物产生耐药性，同时对其他结构无关，作用机理亦各异的药物也产生交叉耐药性，这种独特的广谱耐药现象，是导致肿瘤化疗失败的最主要原因。有关资料统计90%以上肿瘤以及血液病患者死因或多或少都与耐药有关，对肿瘤以及白血病耐药机制的研究一直是耐药逆转研究的中心内容，我们在实验中发现内质网高尔基体中间室标志物一53(ER—Golsiintermediate